Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis, Sanofi SA received a positive opinion ...
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, ...
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals Inc.’s DB-OTO, an AAV-mediated gene ...
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing ...
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for use as an anesthetic.
Actionable intelligence on advances in medical devices and technologies for 20+ years ...
Researchers in the U.K. have developed an AI-driven method of identifying viruses in wild animals with the potential to ...
Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a ...
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals Inc.’s DB-OTO, an AAV-mediated gene ...
With rezpegaldesleukin (rezpeg) phase IIb data in alopecia areata holding strong over time, backers of Nektar Therapeutics ...
Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results